-
Bilex Pharma Announces Breakthrough in Thermostable Vaccine Technology, Enhancing Global Access Potential
Bilex Pharma today announced a significant advancement in its vaccine technology platform, achieving enhanced thermostability for its mRNA vaccine formulations. This breakthrough has the potential to dramatically reduce the reliance on complex ultra-cold chain logistics, a major step towards improving global vaccine access and equity, particularly in resource-limited settings. Overcoming the Cold Chain Challenge Many…
About
At Bilex Pharma, we envision a world where innovative vaccines provide effective protection against both established and emerging infectious diseases, enabling healthier communities and more resilient global health systems.
We focus our expertise on significant health challenges where current solutions are inadequate or nonexistent. By targeting diseases with substantial global burden and limited preventive options, we strive to make meaningful contributions to public health where they’re needed most.
Archive
Categories
Recent Posts
- Bilex Pharma Completes Patient Enrollment for Landmark Phase 3 Trial of RSV Vaccine Candidate BLX-RSV01 in Older Adults
- Bilex Pharma’s Next-Generation COVID-19 Vaccine BLX-COVID19 Shows Superior Immune Response with Reduced Dosing in Phase 2 Trial
- Bilex Pharma Awarded £15 Million Grant from CEPI to Accelerate Development of Pandemic Preparedness Platform
- Bilex Pharma’s Universal Influenza Vaccine Candidate Shows Promising Cross-Strain Protection in Phase 2b Interim Analysis
- Bilex Pharma’s Dengue Vaccine Candidate BLX-DEN01 Demonstrates Balanced Immune Response Against All Four Serotypes in Phase 1 Trial